Key Highlights
- Attruby's US net Revenue reached $180.6 million in Q1 2026, up from $36.7 million a year earlier, but total operating costs of $300.5 million kept the quarterly net loss at $164.0 million.
- BridgeBio has funded its pre-launch build with Debt and preferred Equity rather than common stock: $2.49 billion of total debt plus $1.0 billion of 7.00% preferred converting at $137.79, well above the current price.
- With no Earnings , P/E is not meaningful; the stock trades on roughly 27x trailing and 14.6x forward sales, so returns hinge on the November 2026 and May 2027 FDA decisions.
- BridgeBio Pharma shares closed at $80.09, down $2.05, or 2.50%, on Volume of roughly 2.13 million shares.
A wobble at the end of a transformative year
BridgeBio Pharma ( Nasdaq :BBIO) shares closed at $80.09, down $2.05, or 2.50%, on volume of roughly 2.13 million shares. The dip is noise against the trend: the stock has gained about 76% over 12 months, sits inside a 52-week range of $42.09 to $93.42, and carries a Market Value near $15.7 billion. What changed over that year was not sentiment but the income statement: Attruby (acoramidis), the oral transthyretin stabilizer launched in the US at the end of 2024, has given a perennially loss-making research house a genuine commercial Franchise .
The timing of the slip is worth parsing. On 9 July, Ionis and AstraZeneca disclosed that CARDIO-TTRansform, the Phase 3 study of the TTR silencer eplontersen in ATTR cardiomyopathy, missed its primary endpoint, a composite of cardiovascular mortality and recurrent cardiovascular events through Week 140, when added to standard care that for most participants already included a stabilizer. Among patients taking eplontersen without a stabilizer, a prespecified subgroup, the hazard ratio was a nominally significant 0.71. Read one way that validates stabilizers as the backbone of ATTR-CM treatment; read another, it shows how data-sensitive this market has become. Alnylam, whose Amvuttra is the category's other pillar, is a $27.5 billion company on trailing revenue of $4.8 billion.
What the numbers now look like
First-quarter 2026 results, reported 7 May, showed US Attruby net product revenue of $180.6 million against $36.7 million a year earlier. With $9.5 million of royalties on Beyonttra sales in Europe and Japan and $4.4 million of license and services revenue, total revenue reached $194.5 million versus $116.6 million. Full-year 2025 Attruby sales were $362.4 million on total revenue of $502.1 million, and the sequential curve remains steep: $146.0 million in the fourth quarter of 2025, then $180.6 million in the first of 2026. The company had logged 7,804 unique patient prescriptions from 1,856 prescribers.
Profitability is not close. Operating costs rose to $300.5 million in the quarter from $221.0 million, split between $126.6 million of R&D and $163.9 million of SG&A, the selling line reflecting three launches being staffed at once. Net loss attributable to common stockholders was $164.0 million, or $0.84 per share, barely better than the $167.4 million a year earlier, and the trailing twelve-month loss runs near $722 million. Management has issued no full-year guidance.
The Capital stack is doing heavy lifting
Cash, equivalents and marketable securities stood at $940.2 million, up from $587.5 million at year-end, but only because BridgeBio issued $632.5 million of convertible notes due 2033 in January. Four convertible series (2027, 2029, 2031, 2033) sit on the Balance Sheet , total debt is roughly $2.49 billion, and the net cash position is negative by about $1.55 billion. On 1 July the company raised a further $1.0 billion in Series A cumulative convertible participating preferred stock, with Sixth Street taking $800 million and HealthCare Royalty , a KKR Business , $133.9 million. The paper pays a 7.00% Dividend in kind or cash at BridgeBio's election, converts initially at $137.79, more than double the 30-day volume-weighted average price at signing, steps up to $153.10 after five years, and has no Maturity or holder Redemption right.
For a billion dollars that is unusually shareholder-friendly: conversion dilution only bites far above today's price, though it is expensive if paid-in-kind dividends compound. The board separately authorized a $500 million buyback, an odd companion to fresh preferred issuance unless management believes the burn has peaked.
Europe supplies a cheaper second stream. Bayer sells acoramidis as Beyonttra across the EU under a license that paid $135 million upfront in May 2024, offers up to $150 million in regulatory milestones (of which $75 million landed on European Commission approval), as much as $450 million in sales milestones, and tiered royalties starting in the low-thirties percent of Bayer's net sales. Royalty revenue was only $11.4 million across 2025, but it arrives with almost no cost.
Three filings queued behind Attruby
The company is organized as a portfolio of single-asset subsidiaries, Eidos for acoramidis, QED for infigratinib, Calcilytix for encaleret, ML Bio for BBP-418, alongside minority stakes in GondolaBio (27.5%) and BridgeBio Oncology Therapeutics (18.2%). Three of those Assets are now with the FDA.
BBP-418, an oral therapy for limb-girdle muscular dystrophy type 2I/R9, has Priority Review and a PDUFA date of; the Phase 3 FORTIFY trial showed treated patients improving while placebo patients declined across key measures at the 12-month interim. About 7,000 people in the US and Europe have LGMD2I/R9 or related alpha-dystroglycanopathies, and nothing is approved for any form of LGMD.
Encaleret, for autosomal dominant hypocalcemia type 1, had its NDA accepted on 22 July with a PDUFA date of after the Phase 3 CALIBRATE study met all pre-specified primary and key secondary endpoints; more than 2,100 US patients had been diagnosed under the ADH1 code as of April 2026, and a European filing is planned for the second half of 2026. Infigratinib in achondroplasia met the primary endpoint of the registrational PROPEL 3 study at p<0.0001, with an NDA planned for the third quarter of 2026 and launch guided to early-to-mid 2027. BioMarin's Voxzogo is the incumbent there.
Bull, bear and a multiple that will not settle
The bullish arithmetic is straightforward. Attruby is annualizing above $700 million on US sales alone, Month 54 open-label data from ATTRibute-CM showed a 44.7% reduction in all-cause mortality and a 49.3% reduction in cardiovascular mortality, and eplontersen's miss on top of stabilizer therapy strengthens the case that oral stabilization stays first-line. Three approvals inside roughly nine months would leave BridgeBio with four marketed products, two of them without direct competition.
The bearish case is the balance sheet and the field. Operating cash outflow ran near $444 million over the past year, debt exceeds cash by $1.55 billion, and Book Value per share is negative. Amvuttra is a formidable rival, Pfizer's tafamidis remains entrenched with prescribers, and payer pressure in ATTR-CM will intensify as volumes grow. Short interest of 13.2% of shares outstanding is not the profile of a consensus long.
Valuation gets no anchor from earnings: BridgeBio is loss-making, so a price/earnings ratio is not meaningful. On sales the stock trades near 27 times trailing revenue and 14.6 times forward revenue, with Enterprise value around $17.2 billion. Twenty-two analysts carry an average target of $105.26. That combination says the market pays full freight for Attruby and gives partial Credit for the pipeline, the pending launches are priced, but not priced as certainties.
The near-term test is second-quarter results on 11 August, which will show whether Attruby's sequential climb held up against a fully approved Amvuttra label and whether launch spending is flattening.
Upcoming Catalysts
- Q2 2026 results. First read on Attruby's sequential growth since Alnylam's ATTR-CM label expanded, plus the post-financing cash position.
- ESC Congress, August 2026. Full CARDIO-TTRansform data from Ionis and AstraZeneca will shape how cardiologists sequence stabilizers versus silencers.
- BBP-418 PDUFA. Approval would make it the first therapy for any limb-girdle muscular dystrophy, with launch guided to late 2026 or early 2027.
- Infigratinib NDA submission, Q3 2026. Starts the regulatory clock on the largest of the three pending indications.
- Encaleret PDUFA. An EU filing is also planned for the second half of 2026.
Principal Risks
- Leverage . Total debt of about $2.49 billion against $940.2 million of cash leaves a negative net cash position of roughly $1.55 billion; four convertible series begin maturing in 2027.
- Competitive intensity in ATTR-CM. Pfizer's tafamidis is entrenched and Alnylam's vutrisiran won ATTR-CM approvals in multiple jurisdictions in 2025, pressuring both share and price.
- Regulatory outcomes. Three separate FDA decisions carry the bulk of the pipeline value; a complete response letter on any one would remove a launch from the 2026–2027 revenue bridge.
- Cost of the preferred. The 7.00% dividend may be paid in kind, compounding a claim ahead of common holders if profitability slips further out.
- Small-population commercial risk. Ultra-rare indications such as ADH1 and LGMD2I/R9 depend on diagnosis rates and payer willingness to fund high-priced orphan therapies.
Conclusion
Attruby's US net revenue reached $180.6 million in Q1 2026, up from $36.7 million a year earlier, but total operating costs of $300.5 million kept the quarterly net loss at $164.0 million. Set against that: Total debt of about $2.49 billion against $940.2 million of cash leaves a negative net cash position of roughly $1.55 billion; four convertible series begin maturing in 2027. The next real test: First read on Attruby's sequential growth since Alnylam's ATTR-CM label expanded, plus the post-financing cash position.
This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...